Erasca (ERAS) Competitors

Erasca logo
$15.11 -0.55 (-3.51%)
Closing price 04:00 PM Eastern
Extended Trading
$15.32 +0.21 (+1.39%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

ERAS vs. RVMD, BNTX, ALNY, EXEL, and ASND

Should you buy Erasca stock or one of its competitors? Erasca's main competitors and comparable companies include Revolution Medicines (RVMD), BioNTech (BNTX), Alnylam Pharmaceuticals (ALNY), Exelixis (EXEL), and Ascendis Pharma A/S (ASND). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Erasca compare to Revolution Medicines?

Revolution Medicines (NASDAQ:RVMD) and Erasca (NASDAQ:ERAS) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, risk, analyst recommendations, media sentiment, earnings, valuation, profitability and institutional ownership.

Erasca's return on equity of -31.63% beat Revolution Medicines' return on equity.

Company Net Margins Return on Equity Return on Assets
Revolution MedicinesN/A -84.51% -51.97%
Erasca N/A -31.63%-27.57%

Erasca has lower revenue, but higher earnings than Revolution Medicines. Revolution Medicines is trading at a lower price-to-earnings ratio than Erasca, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Revolution Medicines$197.56M188.63-$1.13B-$9.11N/A
ErascaN/AN/A-$124.55M-$0.95N/A

94.3% of Revolution Medicines shares are held by institutional investors. Comparatively, 67.8% of Erasca shares are held by institutional investors. 7.6% of Revolution Medicines shares are held by insiders. Comparatively, 14.2% of Erasca shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Revolution Medicines presently has a consensus price target of $262.75, suggesting a potential upside of 52.50%. Erasca has a consensus price target of $22.09, suggesting a potential upside of 41.07%. Given Revolution Medicines' stronger consensus rating and higher probable upside, research analysts clearly believe Revolution Medicines is more favorable than Erasca.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Revolution Medicines
1 Sell rating(s)
1 Hold rating(s)
21 Buy rating(s)
1 Strong Buy rating(s)
2.92
Erasca
1 Sell rating(s)
2 Hold rating(s)
8 Buy rating(s)
0 Strong Buy rating(s)
2.64

Revolution Medicines has a beta of 1.44, suggesting that its share price is 44% more volatile than the broader market. Comparatively, Erasca has a beta of 0.68, suggesting that its share price is 32% less volatile than the broader market.

In the previous week, Revolution Medicines had 6 more articles in the media than Erasca. MarketBeat recorded 20 mentions for Revolution Medicines and 14 mentions for Erasca. Revolution Medicines' average media sentiment score of 0.94 beat Erasca's score of 0.08 indicating that Revolution Medicines is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Revolution Medicines
6 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive
Erasca
1 Very Positive mention(s)
2 Positive mention(s)
8 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

Revolution Medicines beats Erasca on 9 of the 15 factors compared between the two stocks.

How does Erasca compare to BioNTech?

BioNTech (NASDAQ:BNTX) and Erasca (NASDAQ:ERAS) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, earnings, dividends, media sentiment, valuation, profitability and institutional ownership.

Erasca has lower revenue, but higher earnings than BioNTech. Erasca is trading at a lower price-to-earnings ratio than BioNTech, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BioNTech$2.42B8.94-$1.29B-$6.85N/A
ErascaN/AN/A-$124.55M-$0.95N/A

In the previous week, Erasca had 5 more articles in the media than BioNTech. MarketBeat recorded 14 mentions for Erasca and 9 mentions for BioNTech. BioNTech's average media sentiment score of 0.38 beat Erasca's score of 0.08 indicating that BioNTech is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
BioNTech
3 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
1 Negative mention(s)
1 Very Negative mention(s)
Neutral
Erasca
1 Very Positive mention(s)
2 Positive mention(s)
8 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

15.5% of BioNTech shares are held by institutional investors. Comparatively, 67.8% of Erasca shares are held by institutional investors. 19.2% of BioNTech shares are held by insiders. Comparatively, 14.2% of Erasca shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

BioNTech has a beta of 1.28, suggesting that its stock price is 28% more volatile than the broader market. Comparatively, Erasca has a beta of 0.68, suggesting that its stock price is 32% less volatile than the broader market.

Erasca has a net margin of 0.00% compared to BioNTech's net margin of -61.39%. BioNTech's return on equity of -4.51% beat Erasca's return on equity.

Company Net Margins Return on Equity Return on Assets
BioNTech-61.39% -4.51% -3.96%
Erasca N/A -31.63%-27.57%

BioNTech currently has a consensus target price of $122.27, suggesting a potential upside of 42.83%. Erasca has a consensus target price of $22.09, suggesting a potential upside of 41.07%. Given BioNTech's stronger consensus rating and higher possible upside, analysts plainly believe BioNTech is more favorable than Erasca.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
BioNTech
1 Sell rating(s)
5 Hold rating(s)
12 Buy rating(s)
1 Strong Buy rating(s)
2.68
Erasca
1 Sell rating(s)
2 Hold rating(s)
8 Buy rating(s)
0 Strong Buy rating(s)
2.64

Summary

BioNTech beats Erasca on 11 of the 16 factors compared between the two stocks.

How does Erasca compare to Alnylam Pharmaceuticals?

Erasca (NASDAQ:ERAS) and Alnylam Pharmaceuticals (NASDAQ:ALNY) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, media sentiment, dividends, institutional ownership and earnings.

Erasca currently has a consensus price target of $22.09, suggesting a potential upside of 41.07%. Alnylam Pharmaceuticals has a consensus price target of $305.86, suggesting a potential upside of 85.33%. Given Alnylam Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Alnylam Pharmaceuticals is more favorable than Erasca.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Erasca
1 Sell rating(s)
2 Hold rating(s)
8 Buy rating(s)
0 Strong Buy rating(s)
2.64
Alnylam Pharmaceuticals
0 Sell rating(s)
10 Hold rating(s)
15 Buy rating(s)
1 Strong Buy rating(s)
2.65

Alnylam Pharmaceuticals has a net margin of 52.85% compared to Erasca's net margin of 0.00%. Alnylam Pharmaceuticals' return on equity of 155.33% beat Erasca's return on equity.

Company Net Margins Return on Equity Return on Assets
ErascaN/A -31.63% -27.57%
Alnylam Pharmaceuticals 52.85%155.33%44.81%

Alnylam Pharmaceuticals has higher revenue and earnings than Erasca. Erasca is trading at a lower price-to-earnings ratio than Alnylam Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ErascaN/AN/A-$124.55M-$0.95N/A
Alnylam Pharmaceuticals$3.71B5.95$313.75M$19.268.57

Erasca has a beta of 0.68, indicating that its stock price is 32% less volatile than the broader market. Comparatively, Alnylam Pharmaceuticals has a beta of 0.43, indicating that its stock price is 57% less volatile than the broader market.

67.8% of Erasca shares are owned by institutional investors. Comparatively, 93.0% of Alnylam Pharmaceuticals shares are owned by institutional investors. 14.2% of Erasca shares are owned by company insiders. Comparatively, 0.9% of Alnylam Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, Alnylam Pharmaceuticals had 2 more articles in the media than Erasca. MarketBeat recorded 16 mentions for Alnylam Pharmaceuticals and 14 mentions for Erasca. Alnylam Pharmaceuticals' average media sentiment score of 0.44 beat Erasca's score of 0.08 indicating that Alnylam Pharmaceuticals is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Erasca
1 Very Positive mention(s)
2 Positive mention(s)
8 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
Alnylam Pharmaceuticals
2 Very Positive mention(s)
4 Positive mention(s)
8 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Neutral

Summary

Alnylam Pharmaceuticals beats Erasca on 14 of the 16 factors compared between the two stocks.

How does Erasca compare to Exelixis?

Erasca (NASDAQ:ERAS) and Exelixis (NASDAQ:EXEL) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, valuation, media sentiment, dividends, analyst recommendations and risk.

Erasca has a beta of 0.68, suggesting that its share price is 32% less volatile than the broader market. Comparatively, Exelixis has a beta of 0.45, suggesting that its share price is 55% less volatile than the broader market.

Exelixis has a net margin of 35.45% compared to Erasca's net margin of 0.00%. Exelixis' return on equity of 45.54% beat Erasca's return on equity.

Company Net Margins Return on Equity Return on Assets
ErascaN/A -31.63% -27.57%
Exelixis 35.45%45.54%33.90%

Exelixis has higher revenue and earnings than Erasca. Erasca is trading at a lower price-to-earnings ratio than Exelixis, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ErascaN/AN/A-$124.55M-$0.95N/A
Exelixis$2.50B6.74$782.57M$3.3420.66

67.8% of Erasca shares are held by institutional investors. Comparatively, 85.3% of Exelixis shares are held by institutional investors. 14.2% of Erasca shares are held by company insiders. Comparatively, 2.6% of Exelixis shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Erasca currently has a consensus target price of $22.09, indicating a potential upside of 41.07%. Exelixis has a consensus target price of $58.62, indicating a potential downside of 15.05%. Given Erasca's stronger consensus rating and higher probable upside, equities research analysts clearly believe Erasca is more favorable than Exelixis.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Erasca
1 Sell rating(s)
2 Hold rating(s)
8 Buy rating(s)
0 Strong Buy rating(s)
2.64
Exelixis
1 Sell rating(s)
10 Hold rating(s)
6 Buy rating(s)
1 Strong Buy rating(s)
2.39

In the previous week, Erasca had 1 more articles in the media than Exelixis. MarketBeat recorded 14 mentions for Erasca and 13 mentions for Exelixis. Exelixis' average media sentiment score of 0.46 beat Erasca's score of 0.08 indicating that Exelixis is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Erasca
1 Very Positive mention(s)
2 Positive mention(s)
8 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
Exelixis
4 Very Positive mention(s)
2 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
2 Very Negative mention(s)
Neutral

Summary

Exelixis beats Erasca on 10 of the 16 factors compared between the two stocks.

How does Erasca compare to Ascendis Pharma A/S?

Erasca (NASDAQ:ERAS) and Ascendis Pharma A/S (NASDAQ:ASND) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, earnings, analyst recommendations, risk, valuation and media sentiment.

Ascendis Pharma A/S has a net margin of 73.26% compared to Erasca's net margin of 0.00%. Ascendis Pharma A/S's return on equity of 32.47% beat Erasca's return on equity.

Company Net Margins Return on Equity Return on Assets
ErascaN/A -31.63% -27.57%
Ascendis Pharma A/S 73.26%32.47%13.26%

Erasca has a beta of 0.68, suggesting that its stock price is 32% less volatile than the broader market. Comparatively, Ascendis Pharma A/S has a beta of 0.4, suggesting that its stock price is 60% less volatile than the broader market.

In the previous week, Ascendis Pharma A/S had 15 more articles in the media than Erasca. MarketBeat recorded 29 mentions for Ascendis Pharma A/S and 14 mentions for Erasca. Ascendis Pharma A/S's average media sentiment score of 0.69 beat Erasca's score of 0.08 indicating that Ascendis Pharma A/S is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Erasca
1 Very Positive mention(s)
2 Positive mention(s)
8 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
Ascendis Pharma A/S
7 Very Positive mention(s)
4 Positive mention(s)
9 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive

Erasca has higher earnings, but lower revenue than Ascendis Pharma A/S. Erasca is trading at a lower price-to-earnings ratio than Ascendis Pharma A/S, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ErascaN/AN/A-$124.55M-$0.95N/A
Ascendis Pharma A/S$814.57M21.09-$258M$15.3018.00

Erasca presently has a consensus price target of $22.09, indicating a potential upside of 41.07%. Ascendis Pharma A/S has a consensus price target of $313.52, indicating a potential upside of 13.85%. Given Erasca's higher probable upside, research analysts plainly believe Erasca is more favorable than Ascendis Pharma A/S.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Erasca
1 Sell rating(s)
2 Hold rating(s)
8 Buy rating(s)
0 Strong Buy rating(s)
2.64
Ascendis Pharma A/S
0 Sell rating(s)
2 Hold rating(s)
19 Buy rating(s)
0 Strong Buy rating(s)
2.90

67.8% of Erasca shares are held by institutional investors. 14.2% of Erasca shares are held by insiders. Comparatively, 40.0% of Ascendis Pharma A/S shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Ascendis Pharma A/S beats Erasca on 11 of the 15 factors compared between the two stocks.

Get Erasca News Delivered to You Automatically

Sign up to receive the latest news and ratings for ERAS and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ERAS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ERAS vs. The Competition

MetricErascaBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$5.52B$4.15B$7.85B$12.17B
Dividend YieldN/A3.62%2.46%4.41%
P/E Ratio-15.2626.5532.9127.37
Price / SalesN/A16.058.595.73
Price / CashN/A26.3721.9322.50
Price / Book14.394.074.403.70
Net Income-$124.55M-$22.86M$3.52B$392.17M
7 Day Performance-3.20%-7.26%-5.34%-4.53%
1 Month Performance12.85%-4.96%-3.61%-5.86%
1 Year Performance485.66%-2.87%0.01%-7.78%

Erasca Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ERAS
Erasca
1.6802 of 5 stars
$15.11
-3.5%
$22.09
+46.2%
+507.0%$5.52BN/AN/A103
RVMD
Revolution Medicines
3.1999 of 5 stars
$172.29
-2.3%
$262.75
+52.5%
+154.3%$38.14B$11.58MN/A883
BNTX
BioNTech
3.6728 of 5 stars
$85.60
+0.7%
$122.27
+42.8%
-17.0%$21.51B$3.25BN/A7,807
ALNY
Alnylam Pharmaceuticals
4.8593 of 5 stars
$165.04
+5.4%
$305.86
+85.3%
-63.3%$20.98B$3.71B8.572,770
EXEL
Exelixis
2.2728 of 5 stars
$69.00
-1.2%
$58.62
-15.1%
+65.7%$17.04B$2.32B20.661,077

Related Companies and Tools


This page (NASDAQ:ERAS) was last updated on 11/16/2026 by MarketBeat.com Staff.
From Our Partners